key: cord-0867833-d9sihzmp
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: Antibody response to the messenger RNA corona virus disease 2019 vaccine in liver transplant recipients
date: 2022-04-28
journal: Hepatol Commun
DOI: 10.1002/hep4.1977
sha: 7a05988ad840e807c40ffadde2862edbb27a3ae1
doc_id: 867833
cord_uid: d9sihzmp

nan

wileyonlinelibrary.com/journal/hep4

To the editor, We would like to share ideas on the article "Antibody response to the messenger RNA-1273 vaccine (Moderna) in liver transplant recipients." [1] Most liver transplant recipients generate an immune response to the Moderna severe acute respiratory syndrome coronavirus 2 messenger RNA-based vaccine, and a limited serologic response is predicted by an immunosuppressive regimen that includes mycophenolate. [1] We agree that the immunologic response to the corona virus disease 2019 (COVID-19) vaccine may differ from that of a healthy person. Immunosuppressive medication may have an impact on vaccination immunologic response. However, we should be aware of the potential impact of asymptomatic COVID-19. Asymptomatic infection is not rare, [2] and it must be ruled out in any investigation of the novel COVID-19 vaccine's efficacy. The immunologic response reported in the current investigation by Cuadrado et al. [1] could be influenced by asymptomatic infection before and after immunization. 

Antibody response to the messenger RNA-1273 vaccine (Moderna) in liver transplant recipients

Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period